Extracranial stereotactic radioablation (ESR) is a new and exiting treatment modality of delivering high dose, hypofractionated irradiation, to extracranial tumors. In the present article we will briefly review the rationale, biological implications of "extreme" hypofractionation, treatment technique and published data. In addition data from an ongoing Phase I clinical trial in patients with clinical stage I, medically inoperable, non-small cell lung cancer, conducted at Indiana University will be presented.
|Original language||English (US)|
|State||Published - Jan 1 2002|
- Biological basis
- Clinical experience
- Stereotactic radioablation
ASJC Scopus subject areas